Spin-In or Spin-Out?: Corporate Venturing in Life Sciences

This paper examines the variety of corporate venturing activities in the pharmaceutical and life science sectors, identifies the range of initiators, motives and structures, and evaluates the potential opportunities for professional venture capital firms. On the one hand, pharmaceutical companies ne...

Full description

Saved in:
Bibliographic Details
Published in:International journal of entrepreneurship and innovation 2000-06, Vol.1 (2), p.109-116
Main Authors: Tidd, Joe, Barnes, Simon
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c833-e0a6c0d2a04ac461db901af2d3dec2544ac958d9df27aa8e72fb219957dd72d93
container_end_page 116
container_issue 2
container_start_page 109
container_title International journal of entrepreneurship and innovation
container_volume 1
creator Tidd, Joe
Barnes, Simon
description This paper examines the variety of corporate venturing activities in the pharmaceutical and life science sectors, identifies the range of initiators, motives and structures, and evaluates the potential opportunities for professional venture capital firms. On the one hand, pharmaceutical companies need to maintain the new product pipeline that has increased the demand for technology acquisition, and on the other, mergers and rationalization within the sector have resulted in a significant growth in technology divestment. Both trends have boosted corporate venturing activity. The study examines the venture activities of nine pharmaceutical firms, fourteen life science companies and seven corporate venture capital funds. The authors conclude that, while there is a wide range of venturing options, there is considerable confusion in the industry over ends and means. Specifically, many firms have failed to differentiate sufficiently between strategic, financial and operational goals, and have therefore created inappropriate forms of corporate venture.
doi_str_mv 10.5367/000000000101298603
format article
fullrecord <record><control><sourceid>sage_cross</sourceid><recordid>TN_cdi_crossref_primary_10_5367_000000000101298603</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.5367_000000000101298603</sage_id><sourcerecordid>10.5367_000000000101298603</sourcerecordid><originalsourceid>FETCH-LOGICAL-c833-e0a6c0d2a04ac461db901af2d3dec2544ac958d9df27aa8e72fb219957dd72d93</originalsourceid><addsrcrecordid>eNp9j01LQkEUhodI6KbtWrXyD0yeOfO9ipAyQXCR-2Gcj1DqXpnJRf--m-ZK8GzewwvP4TyEPDB4lFzpCZyGAUNrFPAr0iAITpUxeE0aJpSkWgK_Ibe1bgEQrbINuX_fbVo6b8ddGR_W5f77aUQG2X_WdPefQ7J6fVlN3-hiOZtPnxc0GM5pAq8CRPQgfBCKxbUF5jNGHlNAKfrWShNtzKi9N0ljXiOzVuoYNUbLhwSPZ0Ppai0pu13ZfPny4xi4Py13rtVDkyNU_Udy225f2v7FS8QviIpKfw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Spin-In or Spin-Out?: Corporate Venturing in Life Sciences</title><source>SAGE</source><creator>Tidd, Joe ; Barnes, Simon</creator><creatorcontrib>Tidd, Joe ; Barnes, Simon</creatorcontrib><description>This paper examines the variety of corporate venturing activities in the pharmaceutical and life science sectors, identifies the range of initiators, motives and structures, and evaluates the potential opportunities for professional venture capital firms. On the one hand, pharmaceutical companies need to maintain the new product pipeline that has increased the demand for technology acquisition, and on the other, mergers and rationalization within the sector have resulted in a significant growth in technology divestment. Both trends have boosted corporate venturing activity. The study examines the venture activities of nine pharmaceutical firms, fourteen life science companies and seven corporate venture capital funds. The authors conclude that, while there is a wide range of venturing options, there is considerable confusion in the industry over ends and means. Specifically, many firms have failed to differentiate sufficiently between strategic, financial and operational goals, and have therefore created inappropriate forms of corporate venture.</description><identifier>ISSN: 1465-7503</identifier><identifier>EISSN: 2043-6882</identifier><identifier>DOI: 10.5367/000000000101298603</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><ispartof>International journal of entrepreneurship and innovation, 2000-06, Vol.1 (2), p.109-116</ispartof><rights>2000 SAGE Publications</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c833-e0a6c0d2a04ac461db901af2d3dec2544ac958d9df27aa8e72fb219957dd72d93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925,79364</link.rule.ids></links><search><creatorcontrib>Tidd, Joe</creatorcontrib><creatorcontrib>Barnes, Simon</creatorcontrib><title>Spin-In or Spin-Out?: Corporate Venturing in Life Sciences</title><title>International journal of entrepreneurship and innovation</title><description>This paper examines the variety of corporate venturing activities in the pharmaceutical and life science sectors, identifies the range of initiators, motives and structures, and evaluates the potential opportunities for professional venture capital firms. On the one hand, pharmaceutical companies need to maintain the new product pipeline that has increased the demand for technology acquisition, and on the other, mergers and rationalization within the sector have resulted in a significant growth in technology divestment. Both trends have boosted corporate venturing activity. The study examines the venture activities of nine pharmaceutical firms, fourteen life science companies and seven corporate venture capital funds. The authors conclude that, while there is a wide range of venturing options, there is considerable confusion in the industry over ends and means. Specifically, many firms have failed to differentiate sufficiently between strategic, financial and operational goals, and have therefore created inappropriate forms of corporate venture.</description><issn>1465-7503</issn><issn>2043-6882</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><recordid>eNp9j01LQkEUhodI6KbtWrXyD0yeOfO9ipAyQXCR-2Gcj1DqXpnJRf--m-ZK8GzewwvP4TyEPDB4lFzpCZyGAUNrFPAr0iAITpUxeE0aJpSkWgK_Ibe1bgEQrbINuX_fbVo6b8ddGR_W5f77aUQG2X_WdPefQ7J6fVlN3-hiOZtPnxc0GM5pAq8CRPQgfBCKxbUF5jNGHlNAKfrWShNtzKi9N0ljXiOzVuoYNUbLhwSPZ0Ppai0pu13ZfPny4xi4Py13rtVDkyNU_Udy225f2v7FS8QviIpKfw</recordid><startdate>200006</startdate><enddate>200006</enddate><creator>Tidd, Joe</creator><creator>Barnes, Simon</creator><general>SAGE Publications</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>200006</creationdate><title>Spin-In or Spin-Out?</title><author>Tidd, Joe ; Barnes, Simon</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c833-e0a6c0d2a04ac461db901af2d3dec2544ac958d9df27aa8e72fb219957dd72d93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tidd, Joe</creatorcontrib><creatorcontrib>Barnes, Simon</creatorcontrib><collection>CrossRef</collection><jtitle>International journal of entrepreneurship and innovation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tidd, Joe</au><au>Barnes, Simon</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Spin-In or Spin-Out?: Corporate Venturing in Life Sciences</atitle><jtitle>International journal of entrepreneurship and innovation</jtitle><date>2000-06</date><risdate>2000</risdate><volume>1</volume><issue>2</issue><spage>109</spage><epage>116</epage><pages>109-116</pages><issn>1465-7503</issn><eissn>2043-6882</eissn><abstract>This paper examines the variety of corporate venturing activities in the pharmaceutical and life science sectors, identifies the range of initiators, motives and structures, and evaluates the potential opportunities for professional venture capital firms. On the one hand, pharmaceutical companies need to maintain the new product pipeline that has increased the demand for technology acquisition, and on the other, mergers and rationalization within the sector have resulted in a significant growth in technology divestment. Both trends have boosted corporate venturing activity. The study examines the venture activities of nine pharmaceutical firms, fourteen life science companies and seven corporate venture capital funds. The authors conclude that, while there is a wide range of venturing options, there is considerable confusion in the industry over ends and means. Specifically, many firms have failed to differentiate sufficiently between strategic, financial and operational goals, and have therefore created inappropriate forms of corporate venture.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><doi>10.5367/000000000101298603</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1465-7503
ispartof International journal of entrepreneurship and innovation, 2000-06, Vol.1 (2), p.109-116
issn 1465-7503
2043-6882
language eng
recordid cdi_crossref_primary_10_5367_000000000101298603
source SAGE
title Spin-In or Spin-Out?: Corporate Venturing in Life Sciences
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T21%3A36%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-sage_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Spin-In%20or%20Spin-Out?:%20Corporate%20Venturing%20in%20Life%20Sciences&rft.jtitle=International%20journal%20of%20entrepreneurship%20and%20innovation&rft.au=Tidd,%20Joe&rft.date=2000-06&rft.volume=1&rft.issue=2&rft.spage=109&rft.epage=116&rft.pages=109-116&rft.issn=1465-7503&rft.eissn=2043-6882&rft_id=info:doi/10.5367/000000000101298603&rft_dat=%3Csage_cross%3E10.5367_000000000101298603%3C/sage_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c833-e0a6c0d2a04ac461db901af2d3dec2544ac958d9df27aa8e72fb219957dd72d93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rft_sage_id=10.5367_000000000101298603&rfr_iscdi=true